> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Organicell Regenerative Medicine IND for COPD Therapy
- URL: https://www.fdaweb.com/organicell-regenerative-medicine-ind-for-copd-therapy/
- Published: 2021-01-28T12:00:00.000Z
- Updated: 2026-09-14T16:44:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148553

FDA has cleared an Organicell Regenerative Medicine IND for Zofin and its use in treating patients diagnosed with chronic obstructive pulmonary disease (COPD). The company has planned an upcoming double blinded, placebo-controlled, Phase 1-2 trial assessing the safety and potential efficacy of intravenous infusion of Zofin in COPD patients. Organicell describes Zofin as an acellular, biologic therapeutic derived from perinatal sources that is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent. “This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues,” it says.